#32026D0381Commission Implementing Decision (EU) 2026/381 postponing the expiry date of the approval of tebuconazole for use in biocidal products of product-type 8
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This Commission Implementing Decision further postpones the expiry date of the approval of the active substance tebuconazole for use in biocidal products of product-type 8 (wood preservatives). The original approval under the old Biocidal Products Directive was set to expire on 31 March 2020. Previous postponements extended it first to 30 September 2022 and then to 30 June 2026. Due to ongoing delays in the evaluation process, particularly the assessment of the substance's endocrine-disrupting properties by the Danish competent authority, the approval is now extended to 30 June 2027. This allows time for the full evaluation, ECHA opinion, and final Commission decision on renewal under Regulation (EU) No 528/2012.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Postpones expiry date of tebuconazole approval for PT8 from 30 June 2026 to 30 June 2027
- Extension granted due to delays in assessing endocrine-disrupting properties by Danish evaluating authority
- Approval remains valid under conditions of Annex I to Directive 98/8/EC during the postponement
+ 1 more changes with Pro
Obligations
What this law requires
Tebuconazole remains approved for use in biocidal products of product-type 8 (wood preservatives) until 30 June 2027, subject to the conditions set out in Annex I to Directive 98/8/EC
The Danish competent authority must complete the full evaluation of tebuconazole's renewal application, including assessment of the substance's endocrine-disrupting properties, within the extended deadline
The European Chemicals Agency (ECHA) must prepare and submit an opinion on renewal of tebuconazole approval to the Commission within 270 days of receipt of the evaluating competent authority's recommendation
The European Commission must make a final decision on whether to renew the approval of tebuconazole for use in biocidal products of product-type 8 by 30 June 2027
Applicants for tebuconazole renewal must provide sufficient data to the Danish evaluating competent authority as requested under Article 8(2) of Regulation (EU) No 528/2012